​

Cardio Diagnostics Stock (NASDAQ:CDIO)

RevenueOwnershipFinancialsChart
Cardio Diagnostics by TradingView

Previous Close

$1.94

52W Range

$0.97 - $7.91

50D Avg

$1.85

200D Avg

$2.93

Market Cap

$4.00M

Avg Vol (3M)

$135.45K

Beta

2.20

Div Yield

-

CDIO Company Profile

Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Jan 14, 2022

Website

CDIO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceMar 25
Reportable Segments$940.00

Fiscal year ends in Dec 25 | Currency in USD

CDIO Financial Summary

Dec 25Dec 24Dec 23
Revenue$14.82K$34.89K$17.07K
Operating Income$-6.48M$-8.37M$-7.24M
Net Income$-6.50M$-8.38M$-8.38M
EBITDA$-6.09M$-8.09M$-1.53M
Basic EPS$-3.71$-9.30$-19.80
Diluted EPS$-3.71$-9.30$-19.80

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
RADXRadiopharm Theranostics Limited
CELZCreative Medical Technology Holdings, Inc.
ADXNAddex Therapeutics Ltd
NRSNNeuroSense Therapeutics Ltd.
ADILAdial Pharmaceuticals, Inc.
BCLIBrainstorm Cell Therapeutics Inc.
BCDABioCardia, Inc.
TCRTAlaunos Therapeutics, Inc.